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Introduction.Data examiningmammographic breast density (MBD) among patients in Sub-SaharanAfrica are sparse.We evaluated
how MBD relates to breast cancer characteristics in Kenyan women undergoing diagnostic mammography. Methods. This cross-
sectional study included women with pathologically confirmed breast cancers (𝑛 = 123). Pretreatment mammograms of the
unaffected breast were assessed to estimate absolute dense area (cm2), nondense area (cm2), and percent density (PD). Relationships
between density measurements and clinical characteristics were evaluated using analysis of covariance. Results. Median PD and
dense area were 24.9% and 85.3 cm2. Higher PD and dense area were observed in younger women (𝑃 < 0.01). Higher dense
and nondense areas were observed in obese women (𝑃-trend < 0.01). Estrogen receptor (ER) positive patients (73%) had higher
PD and dense area than ER-negative patients (𝑃 ≤ 0.02). Triple negative breast cancer (TNBC) patients (17%) had lower PD
and dense area (𝑃 ≤ 0.01) compared with non-TNBCs. No associations were observed between MBD and tumor size and
grade. Conclusions. Our findings show discordant relationships between MBD and molecular tumor subtypes to those previously
observed in Western populations. The relatively low breast density observed at diagnosis may have important implications for
cancer prevention initiatives in Kenya. Subsequent larger studies are needed to confirm these findings.
1. Introduction
Mammographic breast density (MBD) is defined as the rela-
tive amounts of radio dense stromal and epithelial tissue com-
pared with radiolucent adipose tissue. MBD is recognized
as an established independent breast cancer risk factor [1].
It is a heritable trait [2, 3] and is thought to reflect cumulative
exposure to established breast cancer risk factors, including
parity, age at first birth, age at menopause, and endogenous
and exogenous hormonal influences [4–7]. Studies of primar-
ily Western populations have suggested that elevated MBD is
a general marker of breast cancer risk, irrespective ofmolecu-
lar tumor subtype [8]. In addition, elevated MBD has been
associated with adverse breast tumor clinical characteris-
tics including larger tumor size, nodal involvement, and
advanced stage at diagnosis [1, 6, 9]. Relationships between
MBD and adverse prognostic features may reflect decreased
mammographic sensitivity in women with dense breasts,
resulting in delayed diagnosis in screened populations [6].
Furthermore, among women diagnosed with breast cancer,
MBDmay play a role in breast cancer progression [10]. How-
ever, much of the MBD evidence published to date is largely
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based on studies carried out among Western populations
and it is currently unclear whether these findings are similar
among African women.
Little is known about MBD within Sub-Saharan Africa
(SSA), particularly among indigenous women. One study
of 190 Ugandan women without breast cancer, referred for
screening, with an average age of 46 years (standard deviation
(SD) 13 years) at the time of mammography, indicated pos-
sible differences in patterns of MBD from those observed in
the United States (US) or Europe, with a higher proportion of
study participants having lowMBD [11], as defined visually in
categories using the American College of Radiology’s Breast
Imaging Reporting and Data System (BI-RADS) [12]. The
proportion of Ugandan women with low MBD (BI-RADS
category 1) was 41% [11], which is greater than the proportion
of US women in this lowest BI-RADS density category, which
ranges from 0.6 to 9.4%, depending on race, age, and body
mass index (BMI) [13, 14]; BMI was not assessed in the
Ugandan report [11]. Whether differential patterns of MBD
exist and how these MBD patterns relate to breast tumor
characteristics in other regions of SSA is unknown.
In particular, the role of MBD in relation to breast can-
cer clinical characteristics within Kenya is currently unclear.
To investigate this, we performed a cross-sectional analysis,
examining MBD among indigenous Kenyan women with
breast cancer utilizing quantitative software for MBD assess-
ment. We examined relationships between MBD with fea-
tures of breast cancer aggressiveness, including breast molec-
ular tumor subtype and clinicopathological breast cancer
characteristics.
2. Methods
2.1. Study Population. This study was a cross-sectional study
of indigenous Kenyan women with pathologically confirmed
breast cancer, diagnosed between February 2014 and May
2015 at the Aga KhanUniversity Hospital, Nairobi. Diagnoses
were confirmed by a breast pathologist, according to the
National Comprehensive Cancer Network (NCCN) guide-
lines, which are followed as institutional policy for classifica-
tion and treatment related decisions. Overall, 123 women
out of 148 who were diagnosed with breast cancer during
this time-period had pretreatment, diagnostic mammograms
available for assessment. Participant information was ab-
stracted from medical records and a computerized database
included patient age, menopausal status, and BMI. Upon
diagnosis, all breast cancer biopsies underwent a central
pathology reviewwith double reporting of clinical and tumor
characteristics, including tumor size, tumor type, grade, and
lymph nodemetastases. Breast cancer molecular subtype was
defined according to estrogen receptor (ER)/progesterone
receptor (PR) and human epidermal growth factor receptor
2 (HER2) status, which was evaluated using immunohis-
tochemistry on the Dako Automated platform followed by
pathology review (ZM/SS). Interpretation of ER/PRwas done
according to the Allred scoring system [15]. HER2 scoring
was done according to the American Society of Clinical
Oncology (ASCO)/College of American Pathologists (CAP)
guidelines. Samples that scored as HER2 2+ (equivocal) were
subjected to fluorescence in situ hybridization (FISH) testing
to assess gene amplification, at the Aga Khan University Hos-
pital reference laboratory in Karachi Pakistan. A FISH test
result was considered positive if ratio of theHER2/neu/CEP17
signals was >2.2 [16].
All patients were consented for utilization of their infor-
mation in this study. Approvals to conduct this analysis were
obtained from University Research Ethics Committee prior
to the study commencement.
2.2. Assessment of Mammographic Breast Density. MBD was
assessed by a single radiologist (RN) from diagnostic digital
mammograms (mediolateral view) of the unaffected breast,
taken prior to any treatment was instituted, and using the
semiautomated Cumulus 4 Software [17], a well-studied
quantitative method of MBD assessment [6]. Cumulus is a
computer-assisted thresholding program in which the user
defines a threshold for the skin edge and dense area. Three
independent measures of MBD were determined including
percentage density (PD), absolute dense area (cm2), and total
breast area (cm2). PD was calculated by dividing the dense
breast area by the total breast area and multiplying by 100.
Nondense area (cm2) was calculated by subtracting absolute
dense area from the total breast area. The radiologist was
masked to demographic and pathologic data. Quality assur-
ance and reliability assessment of MBD measurements were
performed internally for the first 25 cases using visual assess-
ment by a second radiologist at the Aga Khan University
Hospital, Nairobi. This independent assessment showed 97%
concordance for PD > 50%.
2.3. Statistical Analysis. To examine the relationships be-
tween quantitative MBD measurements and patient and
clinical characteristics, we used analysis of covariance
(ANCOVA) models. Characteristics investigated included
age (<50 years, ≥50 years), menopausal status, BMI (kg/m2
classified according to theWorldHealthOrganization as lean,
overweight and obese) [18], histology (invasive ductal vs.
other), tumor size (<3 cm, ≥3 cm), tumor grade (grade 1,
grade 2, grade 3, and unknown), nodal status (negative, posi-
tive or unknown), ER status (negative, positive, unknown),
PR status (negative, positive, and unknown), HER2 (negative,
positive, and equivocal/ductal carcinoma in situ (DCIS)),
and triple negative breast cancer (TNBC) status [no, yes
(i.e., negative for ER, PR, and HER2), and unknown]. MBD
measurements were square root transformed to better ap-
proximate normal distributions. For ease of interpretation,
the least square means and standard errors from ANCOVA
models were back transformed, and corresponding 95%
confidence intervals were calculated and are presented in the
tables. All models are presented as unadjusted and adjusted
for age and BMI.The results of adjusted models are discussed
below unless otherwise mentioned. In sensitivity analyses,
investigations of relationships between MBD measurements
and molecular tumor subtypes were also stratified by meno-
pausal status. 𝑃 values of <0.05 were considered statistically
significant and tests of statistical significance were two-tailed.
Reported 𝑃 values were not corrected for multiple testing. All
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analyses were performed using SAS software v9.3 (SAS Insti-
tute Inc., Cary, NC).
3. Results
3.1. Overview of Study Population. Patient demographic and
breast tumor clinical characteristics for the overall study pop-
ulation are presented in Table 1. Participant characteristics
stratified by ER status are also shown in Table 1. The median
(range) age at diagnosis was 54 (27–83) years, with most
women being postmenopausal (66%) and overweight/obese
(79%) at diagnosis. Most breast tumors were invasive ductal
(85%), ER-positive (73%), PR-positive (67%), and HER2-
negative (76%). The median (range) tumor size was 3 cm
(0.5–10 cm). A higher proportion of participants had grade
2 tumors (46%) and was positive for lymph node metasta-
sis (49%). Compared with ER-positive breast cancers, ER-
negative tumors tended to be larger, higher grade, and PR-
negative (Table 1). No significant differences were observed
between ER-positive and ER-negative breast tumors for
patient age, menopausal status, BMI, nodal status, and HER2
status (Table 1).
3.2. Relationships between MBD Measurements and Patient
and Clinical Breast Tumor Characteristics. The distributions
of MBD measurements by age are shown in Figure 1 and
Supplementary Figure 1. The median (range) PD was 24.9%
(2.1–76.9%) andmedian (range) dense areawas 85.3 cm2 (1.5–
355.6 cm2). Relationships between MBD measurements and
breast tumor clinical characteristics are shown in Table 2. On
average, significantly higher MBD was observed in younger
(<50 years) versus older (≥50 years) women (adjusted mean
PD: 31.8 versus 19.8%, 𝑃 < 0.01; adjusted mean dense area:
110.1 versus 72.1 cm2, 𝑃 < 0.01). Significantly lower nondense
area was also observed in younger than older women (232.5
versus 306.9 cm2; 𝑃 < 0.02). In unadjusted models, higher
PD and lower nondense area were observed in pre- versus
postmenopausal women (𝑃 < 0.01); however, these findings
were attenuated after adjusting for age and BMI. Significantly
higher dense area and nondense area, reflecting higher total
breast area, were observed in women who were obese versus
overweight/lean (𝑃 values for trend < 0.01 for each); however,
relationships between PD and BMI were not statistically
significant.No relationshipswere observed between theMBD
measurements examined (PD, dense area and nondense area)
and breast tumor, size, grade, and nodal status (Table 2).
3.3. Relationships between MBD Measurements and Breast
Molecular Tumor Subtype. Unadjusted and adjusted relation-
ships between MBD measurements and breast molecular
tumor subtype are shown in Table 3. In addition, because
prior studies have shown that the prevalence of dense
breasts as well as breast cancer molecular subtypes vary by
menopausal status, we carried out sensitivity analyses inves-
tigating relationships between MBDmeasurements and sub-
types also stratified by menopausal status. Compared with
womendiagnosedwith ER-negative tumors, womenwith ER-
positive tumors had significantly higher PD and dense area
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Figure 1: Distribution of mammographic percent breast density
(PD) measurements by age.
(for PD: 25.8% versus 19.3%, 𝑃 = 0.02; and for dense area:
94.4 versus 63.2 cm2,𝑃 = 0.01) (Table 3).These patterns were
consistent albeit attenuated when analyses were stratified
by menopausal status. No significant relationships were
observed between MBD measurements and either PR or
HER2 status. In contrast, TNBCbreast cancer cases had signi-
ficantly lower PD and dense area as compared with non-
TNBC subtypes (for PD: 17.4 versus 26.1%, 𝑃 = 0.01, and for
dense area: 56.3 versus 96.6 cm2,𝑃 < 0.01), findings that were
most apparent, albeit attenuated, among premenopausal
women. Overall, no relationships were observed between
nondense area and any of the breast cancer molecular
subtypes examined.
4. Discussion
This study is the first to present data from indigenous Kenyan
women showing relationships between breast cancer clinical
characteristics and MBD. To date, much of the literature
surrounding MBD has focused on Western populations. In
this analysis, we show inverse relationships between MBD
and patient age, which are consistent with Western trends
[7], with higher PD and dense area observed in younger than
older women. Similar inverse associations were found for
MBD and menopausal status, with higher MBD observed
among premenopausal compared with postmenopausal
women. In contrast to Western populations of screened
women [10, 19, 20], we did not identify relationships between
MBD measurements and breast cancer prognostic features
such as tumor size, grade, and nodal status. However, we did
find significant differences in MBD measures by molecular
tumor subtype, with higher PD and absolute dense area for
women who were positive for ER expression and lower PD
and absolute dense area for women with TNBC.
As highlighted in the Introduction section, a prior analy-
sis of MBD among Ugandan women referred for mammo-
graphic screening and without breast cancer found that a
large proportion of study participants had low breast density
(BI-RADS category 1 and 2; 67.9%) [11]. This proportion is
higher than studies among Western populations, including
4 BioMed Research International
Table 1: Select characteristics of breast cancer patients with pretreatment diagnostic mammograms, Aga Khan University Hospital, Kenya,
2014-2015.
Clinical characteristic Overall (𝑛 = 123) ER-positive (𝑛 = 90) ER-negative (𝑛 = 33)
𝑛 (%) 𝑛 (%) 𝑛 (%)
Age
<50 years 48 39 37 41 11 33
≥50 years 75 61 53 59 22 67
Mean (years), SD 54 (11) 53 (11) 57 (12)
Median (range) 54 (27-83) 54 (27-81) 54 (39-83)
Menopausal status
Pre 42 34 33 37 9 27
Post 81 66 57 63 24 73
BMI category
Lean 18 15 13 14 5 15
Overweight 54 44 40 44 14 42
Obese 43 35 32 36 11 33
Missing 8 7 5 6 3 9
Mean (kg/m2), SD 29 (4.8) 29 (4.7) 28 (5.3)
Median (range) 28 (18-46.8) 28 (19-45.6) 28 (18-46.8)
Diagnosis
Invasive ductal 105 85 77 86 28 85
Other 18 15 13 14 5 15
Tumor size
<3 cm 53 43 44 49 9 27
≥3 cm 58 47 39 43 19 58
Missing 12 10 7 8 5 15
Mean (cm), SD 3.3 (1.8) 3.3 (1.8) 3.4 (1.9)
Median (range) 3 (0.5-10) 2.7 (1-10) 3 (0.5-8)
Tumor grade
Grade 1 14 11 13 14 1 3
Grade 2 57 46 51 57 6 18
Grade 3 49 40 25 28 24 73
Missing 3 2 1 1 2 6
Nodal status
Negative 49 40 36 40 13 39
Positive 60 49 46 51 14 42
Missing 14 11 8 9 6 18
PR status
Negative 40 33 9 10 31 94
Positive 83 67 81 90 2 6
HER2 status
Negative 94 76 71 79 23 70
Positive 22 18 14 16 8 24
Equivocal/DCIS 7 6 5 6 2 6
TNBC status
Negative 95 77 85 94 10 30
Positive 21 17 0 0 21 64
Missing 7 6 5 6 2 6
BMI: bodymass index; ER: estrogen receptor;HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; TNBC: triple negative breast cancer.
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a study of MBD among patients undergoing a breast biopsy
following an abnormal mammogramwhich found that about
40% of African-American patients had MBD of either BI-
RADs category 1 or 2, which roughly reflects PD < 50%
[14]. Within our study population, the mean PD was 26.6%,
with most (89%) women having PD measurements less than
50%. These distributions are comparable to those found
among the screening population in Uganda, although BI-
RADs measurements were utilized in Uganda. Studies that
have examined the relationship between MBD and race
have found mixed results to date and often yielded differing
findings following the inclusion of age, BMI, and breast size
as adjustments factors, all of which vary between populations
[13]. The high proportion of lower breast density observed
in SSA could be partly accounted for by elevated BMI, as
an increase in breast size associated with a higher BMI may
result in lower percentage breast density. However, BMI was
not reported in the prior Ugandan study and thus a strength
of this study was our ability to account for this influence by
including BMI as an adjustment factor within our analysis.
Among breast cancer patients within SSA, it is recognized
that there are differences in breast cancer characteristics com-
pared with Western populations. Findings of a recent meta-
analysis by Jedy-Agba and colleagues, which included 83
studies from 17 countries in SSA and reviewed breast cancer
diagnosis stage in this setting, found that 77% of breast
cancer patients were diagnosed with stage 3/4 disease and
10–15 years younger than in developed countries [21, 22].
In agreement with that meta-analysis, our study population
had a high proportion of tumors that were larger, higher
grade, and positive for lymph node metastasis. Our study
showed no association between these prognostic characteris-
tics and MBD measurements. While to our knowledge these
relationships have not been previously investigated in Kenya,
these findings contrast with a larger case-control study nested
within the Nurses’ Health Study prospective cohort, which
found that elevated MBD was associated with larger, higher
grade tumors [20].
The literature investigating relationships between MBD
and breast cancer molecular subtypes defined according to
hormone receptor status have also been inconsistent to date.
A meta-analysis conducted by Antoni and colleagues that is
consisted of over 24,000 breast cancer cases from 19 studies
found that themagnitudes of the relationships betweenMBD
and risk of ER-positive and ER-negative breast cancer were
similar, highlighting that MBD is a strong marker of breast
cancer risk irrespective of clinical subtype [8]. However, it is
important to note that the majority of the studies included in
that meta-analysis were based within US and European pop-
ulations [8]. We showed higher MBD measurements among
women with ER-positive than ER-negative breast cancers,
findings that were attenuated when stratified by menopausal
status. While these findings could be an artifact of a smaller
sample size of ER-negative breast cancers, these relationships
are likely influenced bymultiple factors that could affect both
MBD and ER-status, including menopausal status [23]. Of
note in this study, a higher proportion of ER-positive com-
pared to ER-negative breast cancer cases was premenopausal
at diagnosis. MBD is inversely associated with menopausal
status and is higher in younger premenopausal women in
this and other populations [23]. In analyses stratified by
menopausal status, differences in MBD by ER status were
attenuated among premenopausal women. Future studies
with larger numbers of ER-positive and ER-negative breast
cancers from pre- and postmenopausal women are needed to
clarify these relationships among African women. The find-
ings observed for lower PD and absolute dense area among
womenwith TNBC are consistent with our findings of higher
MBD measurements observed for women positive for ER
expression.
A high proportion of low MBD in SSA, particularly
among indigenous Kenyan women may have important im-
plications for the application of cancer prevention initiatives.
For example, lower resource settings, where it may not be
feasible to establish large population-based screening pro-
grams for breast cancer, may obtain greater benefits from
inexpensive and relatively safe breast cancer screening tools,
such as mammography or ultrasound. This is particularly
relevant in a resource challenged setting like Kenya, where
breast cancer remains the most common cancer of women,
with an age-standardized incidence rate of 51.7 per 100,000
[24].
This analysis is one of the first to date to investigate the
role of MBD among indigenous Kenyan women with breast
cancer. In addition, the use of computer-assisted software for
breast density assessment allows for quantitative interpreta-
tion of MBD measures, reducing the potential biases associ-
ated with visual assessment. The population included in this
analysis was not enrolled in a breast cancer screening pro-
gram and thus their diagnoses were based upon presentation
of symptoms or evaluation of breast lumps. Therefore, this
provides a unique opportunity to examine relationships be-
tweenMBDandbreast tumormolecular subtypeswithout the
influence of screening. Limited data, however, were available
on traditional breast cancer risk factors including family
history and reproductive factors such as parity. Therefore,
future studies will be needed to determine whether the
observed relationships betweenMBD and ER-positive versus
ER-negative breast cancer are influenced by these factors.
Expanded ongoing efforts in Kenya to understand the role of
MBD in breast cancer risk and progression will further
complement this analysis. Kenya’s participation in the Inter-
national Consortium of Mammographic Density, a consor-
tium developed by the International Agency for Research on
Cancer (IARC), whose goal is to pool international MBD
data onwomenwithout breast cancer, will allow for increased
understanding of the role of MBD in breast cancer etiology
within this population and will also allow in-depth investi-
gation of MBD in Kenya and its comparability with other
countries [25].
It is acknowledged that the landscape of breast cancer in
Africa is changing with increased incidence and mortality
being observed over the last 20 years. As the drivers of these
trends are not fully elucidated, it is important to better under-
stand factors that may influence breast tumor development
and progression. This study is a first step in understanding
MBD from aKenyan andAfrican perspective in a clinical set-
ting. The differential patterns of association observed within
BioMed Research International 9
this population forMBD by ER status suggest that MBD con-
tributes to ER-positive and ER-negative breast cancers poten-
tially through differential mechanisms. Identifying factors
specific to breast cancermolecular subtypeswill help improve
our understanding of ER-positive versus ER-negative tumor
etiology and progression.
In conclusion, we present results from indigenousKenyan
breast cancer patients that offer further insights into the role
ofMBD in breast cancer.This study provides a foundation for
expanding efforts to investigate the role ofMBD in breast can-
cer risk and prognosis in Kenya and to understand geograph-
ical variation in MBD between Kenya and other countries
worldwide. Additional larger multicenter studies in inde-
pendent validation populations are needed to confirm these
findings.
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